Benralizumab: an updated treatment of eosinophilic asthma

被引:15
作者
Cushen, Breda [1 ]
Menzies-Gow, Andrew [1 ]
机构
[1] Royal Brompton Hosp, Dept Resp Med, Sydney St, London SW3 6NP, England
关键词
Asthma; anti-IL5; therapy; anti-eosinophilic therapy; Benralizumab; efficacy; safety; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; UNCONTROLLED ASTHMA; PLACEBO; RECEPTOR; INFLAMMATION; MEPOLIZUMAB; EFFICACY; SAFETY; ANTI-INTERLEUKIN-5;
D O I
10.1080/17476348.2020.1739526
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: An estimated 5-10% of people with asthma have disease which remains uncontrolled despite maximal treatment with inhaled corticosteroids and long-acting beta-agonists. Benralizumab is currently licensed for use in patients with severe asthma who have an eosinophilic phenotype. Benralizumab depletes eosinophils by binding to the anti-IL5 receptor on the surface of eosinophils, mitigating the effect of IL-5 on eosinophil proliferation and survival, and induces natural killer cell-mediated eosinophil apoptosis. Areas covered: The authors review the mechanism of action and pharmacokinetic profile of Benralizumab and summarize the scientific data supporting its clinical efficacy and safety in severe asthma. Further, the authors highlight future studies of Benralizumab in asthma and other diseases. Expert opinion: Benralizumab lowers exacerbation rates, symptom burden, and oral glucocorticoid use, and improves lung function, in patients with severe eosinophilic asthma. Benralizumab is well tolerated and is an attractive choice for patients and physicians due to its eosinophil-depleting mechanism of action and less frequent dosing schedule. More data is needed to guide the selection of biologic therapy in severe asthma patients.
引用
收藏
页码:435 / 444
页数:10
相关论文
共 50 条
[41]   Trends of therapy in the treatment of asthma [J].
Lv, Xiaodi ;
Gao, Zhen ;
Tang, Weifeng ;
Qin, Jingjing ;
Wang, Wenqian ;
Liu, Jiaqi ;
Li, Mihui ;
Teng, Fangzhou ;
Yi, La ;
Dong, Jingcheng ;
Wei, Ying .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2023, 17
[42]   Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab [J].
Ridolo, Erminia ;
Pucciarini, Francesco ;
Nizi, Maria Cristina ;
Makri, Eleni ;
Kihlgren, Paola ;
Panella, Lorenzo ;
Incorvaia, Cristoforo .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (10) :2349-2356
[43]   Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis [J].
Desaintjean, Charlene ;
Ahmad, Kais ;
Traclet, Julie ;
Gerfaud-Valentin, Mathieu ;
Durel, Cecile-Audrey ;
Glerant, Jean-Charles ;
Hot, Arnaud ;
Lestelle, Francois ;
Mainbourg, Sabine ;
Nasser, Mouhamad ;
Seve, Pascal ;
Turquier, Segolene ;
Devouassoux, Gilles ;
Cottin, Vincent .
FRONTIERS IN MEDICINE, 2024, 11
[44]   Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study) [J].
Wedner, H. James ;
Fujisawa, Takao ;
Guilbert, Theresa W. ;
Ikeda, Masanori ;
Mehta, Vinay ;
Tam, Jonathan S. ;
Lukka, Pradeep B. ;
Asimus, Sara ;
Durzynski, Tomasz ;
Johnston, James ;
White, Wendy I. ;
Shah, Mihir ;
Werkstroem, Viktoria ;
Jison, Maria L. .
PEDIATRIC ALLERGY AND IMMUNOLOGY, 2024, 35 (03)
[45]   Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient [J].
Rogers, Linda ;
Jesenak, Milos ;
Bjermer, Leif ;
Hanania, Nicola A. ;
Seys, Sven F. ;
Diamant, Zuzana .
RESPIRATORY MEDICINE, 2023, 218
[46]   Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study) [J].
Martinez-Moragon, Eva ;
Garcia-Moguel, Ismael ;
Nuevo, Javier ;
Resler, Gustavo .
BMC PULMONARY MEDICINE, 2021, 21 (01)
[47]   Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma [J].
Khatri, Sumita ;
Moore, Wendy ;
Gibson, Peter G. ;
Leigh, Richard ;
Bourdin, Arnaud ;
Maspero, Jorge ;
Barros, Manuel ;
Buhl, Roland ;
Howarth, Peter ;
Albers, Frank C. ;
Bradford, Eric S. ;
Gilson, Martyn ;
Price, Robert G. ;
Yancey, Steven W. ;
Ortega, Hector .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (05) :1742-+
[48]   Advancements in biologic therapy in eosinophilic asthma [J].
Patadia, Rini ;
Casale, Thomas B. ;
Fowler, John ;
Patel, Shiven ;
Cardet, Juan Carlos .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (04) :251-261
[49]   Primary care of asthma: new options for severe eosinophilic asthma [J].
Skolnik, Neil S. ;
Carnahan, Sean P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) :1309-1318
[50]   Emerging Therapies in Severe Eosinophilic Asthma [J].
Pang, Pee Hwee ;
Brightling, Christopher E. .
ARCHIVOS DE BRONCONEUMOLOGIA, 2017, 53 (05) :233-234